STAA 8-K
Staar Surgical Co (STAA)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code:
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 under the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 18, 2025, STAAR Surgical Company (the “Company”) held its 2025 Annual Meeting of Shareholders (the “2025 Annual Meeting”). At the 2025 Annual Meeting, the Company’s shareholders voted upon three proposals, each as described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 24, 2025. As of April 22, 2025, the record date for the 2025 Annual Meeting, there were 49,526,129 outstanding shares of the Company's common stock. At the 2025 Annual Meeting, a quorum of 44,746,693 shares of the Company’s common stock were represented in person or by proxy. The final voting results with respect to each of the three proposals considered and voted upon at the 2025 Annual Meeting are set forth below.
Proposal 1: To elect six directors to serve for a term of office expiring at the Company's 2026 Annual Meeting of Shareholders or until their successors are duly elected and qualified:
|
Number of Shares |
||
For |
Withheld |
Broker Non-Votes |
|
Arthur C. Butcher |
41,076,988 |
1,128,266 |
2,541,439 |
Stephen C. Farrell |
42,142,992 |
62,262 |
2,541,439 |
Wei Jiang |
41,337,072 |
868,182 |
2,541,439 |
Louis E. Silverman |
42,148,565 |
56,689 |
2,541,439 |
Elizabeth Yeu, MD |
41,809,829 |
395,425 |
2,541,439 |
Lilian Y. Zhou |
41,898,816 |
306,438 |
2,541,439 |
Proposal 2: To ratify the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending January 2, 2026:
Number of Shares |
||
For |
Against |
Abstain |
44,463,071 |
273,085 |
10,537 |
Proposal 3: To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers:
Number of Shares |
|||
For |
Against |
Abstain |
Broker Non-Votes |
41,130,690 |
1,049,897 |
24,667 |
2,541,439 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STAAR Surgical Company |
||
|
||
June 18, 2025 |
By: |
/s/ Stephen C. Farrell |
|
|
Stephen C. Farrell |
|
|
Chief Executive Officer |